BridgeBio Pharma
BBIO
BBIO
164 hedge funds and large institutions have $1.28B invested in BridgeBio Pharma in 2022 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 59 increasing their positions, 59 reducing their positions, and 26 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
8% less funds holding
Funds holding: 178 → 164 (-14)
12% less capital invested
Capital invested by funds: $1.45B → $1.28B (-$179M)
35% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 26
Holders
164
Holding in Top 10
4
Calls
$9.02M
Puts
$3.53M
Top Buyers
| 1 | +$15.9M | |
| 2 | +$7.07M | |
| 3 | +$4.56M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.28M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$4.14M |
Top Sellers
| 1 | -$19.5M | |
| 2 | -$12.1M | |
| 3 | -$7.24M | |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$6.77M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$5.23M |